



Figure S1. Comparison of survival outcomes according to different ICIs: (a) PD-L1 < 1%; (b) PD-L1 1–49%; and (c) PD-L1 ≥ 50%. Data of 162 patients with confirmed PD-L1 expressions were analyzed. No patient was treated with pembrolizumab in the PD-L1 < 1% subgroup.